Leadership Team

Roger M. Boissonneault
Chief Executive Officer, President and Director

Roger M. Boissonneault, Chief Executive Officer, President and Director, was appointed President and Director of the Company as of January 5, 2005. Mr. Boissonneault was appointed Chief Executive Officer and Director for Warner Chilcott PLC (the predecessor of the Company) in September 2000. He previously served as President and Chief Operating Officer of Warner Chilcott PLC (the predecessor company acquired by Warner Chilcott PLC in September 2000) from 1996 to 2000, serving as a director from 1998 through 2000. From 1976 to 1996 Mr. Boissonneault served in various capacities with Warner-Lambert, including Vice President, Female Healthcare, Director of Corporate Strategic Planning, and Director of Obstetrics/Gynecology Marketing.

W. Carlton Reichel
President, Pharmaceuticals

W. Carl Reichel, President, Pharmaceuticals, joined Warner Chilcott PLC (the predecessor of the Company) as President in October 2000 after nearly 20 years of experience at Parke-Davis, a division of Warner-Lambert (now a part of Pfizer), where he, together with Mr. Boissonneault, was a pioneer in the pharmaceutical marketing methods currently employed by us. Most recently, he held the position of President, U.K./British Isles at Warner-Lambert.

Anthony D. Bruno
Executive Vice President, Corporate Development

Anthony D. Bruno, Executive Vice President, Corporate Development, joined Warner Chilcott PLC (the predecessor of the Company) in March 2001 as Senior Vice President, Corporate Development and General Counsel. Mr. Bruno was promoted to Executive Vice President in April 2003 and continued to serve as General Counsel of the Company until August 1, 2005. Prior to joining the Company, Mr. Bruno spent 17 years with Warner-Lambert where his most recent position was Vice President and Associate General Counsel, Pharmaceuticals, and he was responsible for all legal matters relating to Warner-Lambert's pharmaceutical business worldwide.

Paul Herendeen
Executive Vice President and Chief Financial Officer

Paul Herendeen, Executive Vice President and Chief Financial Officer, joined Warner Chilcott in this position on April 1, 2005 and is responsible for our finance, accounting, treasury and management information system functions. Prior to joining Warner Chilcott, Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. From 1998 through March 2001, Mr. Herendeen served as Executive Vice President and Chief Financial Officer of the predecessor company acquired by Warner Chilcott PLC in September 2000. Mr. Herendeen also served as a director of Warner Chilcott PLC from October 2000 through March 2001.

Leland H. Cross
Senior Vice President, Technical Operations

Leland H. Cross, Senior Vice President, Technical Operations, joined Warner Chilcott PLC (the predecessor of the Company) in this position on September 1, 2001 and is responsible for our technical operations worldwide. From 1994 to 2001, Mr. Cross was part of the Global Manufacturing group at Warner-Lambert (which became part of Pfizer in June 2000), where most recently he was General Manager of Pfizer Ireland Pharmaceuticals, responsible for Pfizer's dosage manufacturing operations in Ireland. Prior to joining Warner-Lambert, Mr. Cross managed a manufacturing operation for Merck & Co. Inc.

Herman Ellman M.D.
Senior Vice President, Clinical Development

Herman Ellman, M.D., Senior Vice President, Clinical Development, joined Warner Chilcott PLC (the predecessor of the Company) in this position in June 2000. Dr. Ellman is responsible for clinical development and medical affairs activities. Prior to joining Warner Chilcott PLC, Dr. Ellman held the position of Medical Director for Women's Healthcare of Berlex Laboratories.

Izumi Hara
Senior Vice President, General Counsel and Corporate Secretary

Izumi Hara, Senior Vice President, General Counsel and Corporate Secretary, joined Warner Chilcott PLC (the predecessor of the Company) as Senior Vice President and Deputy General Counsel in June 2001 and is responsible for the legal matters of the Company. She was promoted to General Counsel as of August 1, 2005. Prior to joining Warner Chilcott PLC, Ms. Hara held positions of increasing responsibility at Warner- Lambert where her most recent position was Vice President and Associate General Counsel, Corporate Affairs, where she was responsible for all corporate legal matters, including acquisitions, divestitures, alliances and other transactions in all of Warner-Lambert's lines of business worldwide.

Alvin Howard
Senior Vice President, Regulatory Affairs

Alvin D. Howard, Senior Vice President, Regulatory Affairs, joined Warner Chilcott PLC (the predecessor of the Company) as Vice President, Regulatory Affairs in February 2001. He was promoted to Senior Vice President as of August 1, 2005 and is responsible for the registration of all of our products and for managing our relationships with the FDA, Health Canada and other agencies regulating the sale of pharmaceutical products. Prior to joining the Company, Mr. Howard was Vice President, Worldwide Regulatory Affairs at Roberts Pharmaceuticals.